Satoshi Miyamoto

AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function

Laura L. Dugan, Young-Hyun You, Sameh S. Ali et al. · Journal of Clinical Investigation · 2013 · 442 citations · Full text

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

Ryo Kodera, Kenichi Shikata, Hitomi Kataoka et al. · Diabetologia · 2011 · 378 citations · Full text

Inflammation, Metabolic Syndrome, Type 1 +11

Mass Spectrometry Imaging Reveals Elevated Glomerular ATP/AMP in Diabetes/obesity and Identifies Sphingomyelin as a Possible Mediator

Satoshi Miyamoto, Cheng‐Chih Hsu, Grégory Hamm et al. · EBioMedicine · 2016 · 121 citations · Full text

Metabolic Disorder, Identifies Sphingomyelin, Renal Pathology +24

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes

Ryo Kodera, Kenichi Shikata, Tetsuharu Takatsuka et al. · Biochemical and Biophysical Research Communications · 2013 · 99 citations

Inflammation, Type 1, Urology +14

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 88 citations · Full text